TY - JOUR A1 - Jaite, Charlotte A1 - Bühren, Katharina A1 - Dahmen, Brigitte A1 - Dempfle, Astrid A1 - Becker, Katja A1 - Correll, Christoph U. A1 - Egberts, Karin M. A1 - Ehrlich, Stefan A1 - Fleischhaker, Christian A1 - von Gontard, Alexander A1 - Hahn, Freia A1 - Kolar, David A1 - Kaess, Michael A1 - Legenbauer, Tanja A1 - Renner, Tobias J. A1 - Schulze, Ulrike A1 - Sinzig, Judith A1 - Thomae, Ellen A1 - Weber, Linda A1 - Wessing, Ida A1 - Antony, Gisela A1 - Hebebrand, Johannes A1 - Föcker, Manuel A1 - Herpertz-Dahlmann, Beate T1 - Clinical Characteristics of Inpatients with Childhood vs. Adolescent Anorexia Nervosa JF - Nutrients N2 - We aimed to compare the clinical data at first presentation to inpatient treatment of children (<14 years) vs. adolescents (≥14 years) with anorexia nervosa (AN), focusing on duration of illness before hospital admission and body mass index (BMI) at admission and discharge, proven predictors of the outcomes of adolescent AN. Clinical data at first admission and at discharge in 289 inpatients with AN (children: n = 72; adolescents: n = 217) from a German multicenter, web-based registry for consecutively enrolled patients with childhood and adolescent AN were analyzed. Inclusion criteria were a maximum age of 18 years, first inpatient treatment due to AN, and a BMI <10th BMI percentile at admission. Compared to adolescents, children with AN had a shorter duration of illness before admission (median: 6.0 months vs. 8.0 months, p = 0.004) and higher BMI percentiles at admission (median: 0.7 vs. 0.2, p = 0.004) as well as at discharge (median: 19.3 vs. 15.1, p = 0.011). Thus, in our study, children with AN exhibited clinical characteristics that have been associated with better outcomes, including higher admission and discharge BMI percentile. Future studies should examine whether these factors are actually associated with positive long-term outcomes in children. KW - anorexia nervosa KW - children KW - adolescents KW - clinical characteristics KW - BMI KW - outcome Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-193160 SN - 2072-6643 VL - 11 IS - 11 ER - TY - JOUR A1 - Jarick, I. A1 - Volckmar, A. L. A1 - Pütter, C. A1 - Pechlivanis, S. A1 - Nguyen, T. T. A1 - Dauvermann, M. R. A1 - Beck, S. A1 - Albayrak, Ö. A1 - Scherag, S. A1 - Gilsbach, S. A1 - Cichon, S. A1 - Hoffmann, P. A1 - Degenhardt, F. A1 - Nöthen, M. M. A1 - Schreiber, S. A1 - Wichmann, H. E. A1 - Jöckel, K. H. A1 - Heinrich, J. A1 - Tiesler, C. M. T. A1 - Faraone, S. V. A1 - Walitza, S. A1 - Sinzig, J. A1 - Freitag, C. A1 - Meyer, J. A1 - Herpertz-Dahlmann, B. A1 - Lehmkuhl, G. A1 - Renner, T. J. A1 - Warnke, A. A1 - Romanos, M. A1 - Lesch, K. P. A1 - Reif, A. A1 - Schimmelmann, B. G. A1 - Hebebrand, J. A1 - Scherag, A. A1 - Hinney, A. T1 - Genome-wide analysis of rare copy number variations reveals PARK2 as a candidate gene for attention-deficit/hyperactivity disorder JF - Molecular Psychiatry N2 - Attention-deficit/hyperactivity disorder (ADHD) is a common, highly heritable neurodevelopmental disorder. Genetic loci have not yet been identified by genome-wide association studies. Rare copy number variations (CNVs), such as chromosomal deletions or duplications, have been implicated in ADHD and other neurodevelopmental disorders. To identify rare (frequency ≤1%) CNVs that increase the risk of ADHD, we performed a whole-genome CNV analysis based on 489 young ADHD patients and 1285 adult population-based controls and identified one significantly associated CNV region. In tests for a global burden of large (>500 kb) rare CNVs, we observed a nonsignificant (P=0.271) 1.126-fold enriched rate of subjects carrying at least one such CNV in the group of ADHD cases. Locus-specific tests of association were used to assess if there were more rare CNVs in cases compared with controls. Detected CNVs, which were significantly enriched in the ADHD group, were validated by quantitative (q)PCR. Findings were replicated in an independent sample of 386 young patients with ADHD and 781 young population-based healthy controls. We identified rare CNVs within the parkinson protein 2 gene (PARK2) with a significantly higher prevalence in ADHD patients than in controls \((P=2.8 × 10^{-4})\) after empirical correction for genome-wide testing). In total, the PARK2 locus (chr 6: 162 659 756-162 767 019) harboured three deletions and nine duplications in the ADHD patients and two deletions and two duplications in the controls. By qPCR analysis, we validated 11 of the 12 CNVs in ADHD patients \((P=1.2 × 10^{-3})\) after empirical correction for genome-wide testing). In the replication sample, CNVs at the PARK2 locus were found in four additional ADHD patients and one additional control \((P=4.3 × 10^{-2})\). Our results suggest that copy number variants at the PARK2 locus contribute to the genetic susceptibility of ADHD. Mutations and CNVs in PARK2 are known to be associated with Parkinson disease. KW - children KW - ADHD KW - CNVs KW - GWAS KW - PARK2 Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-121131 VL - 19 IS - 19 ER - TY - JOUR A1 - Kaiser, Anna A1 - Aggensteiner, Pascal-M. A1 - Holtmann, Martin A1 - Fallgatter, Andreas A1 - Romanos, Marcel A1 - Abenova, Karina A1 - Alm, Barbara A1 - Becker, Katja A1 - Döpfner, Manfred A1 - Ethofer, Thomas A1 - Freitag, Christine M. A1 - Geissler, Julia A1 - Hebebrand, Johannes A1 - Huss, Michael A1 - Jans, Thomas A1 - Jendreizik, Lea Teresa A1 - Ketter, Johanna A1 - Legenbauer, Tanja A1 - Philipsen, Alexandra A1 - Poustka, Luise A1 - Renner, Tobias A1 - Retz, Wolfgang A1 - Rösler, Michael A1 - Thome, Johannes A1 - Uebel-von Sandersleben, Henrik A1 - von Wirth, Elena A1 - Zinnow, Toivo A1 - Hohmann, Sarah A1 - Millenet, Sabina A1 - Holz, Nathalie E. A1 - Banaschewski, Tobias A1 - Brandeis, Daniel T1 - EEG data quality: determinants and impact in a multicenter study of children, adolescents, and adults with attention-deficit/hyperactivity disorder (ADHD) JF - Brain Sciences N2 - Electroencephalography (EEG) represents a widely established method for assessing altered and typically developing brain function. However, systematic studies on EEG data quality, its correlates, and consequences are scarce. To address this research gap, the current study focused on the percentage of artifact-free segments after standard EEG pre-processing as a data quality index. We analyzed participant-related and methodological influences, and validity by replicating landmark EEG effects. Further, effects of data quality on spectral power analyses beyond participant-related characteristics were explored. EEG data from a multicenter ADHD-cohort (age range 6 to 45 years), and a non-ADHD school-age control group were analyzed (n\(_{total}\) = 305). Resting-state data during eyes open, and eyes closed conditions, and task-related data during a cued Continuous Performance Task (CPT) were collected. After pre-processing, general linear models, and stepwise regression models were fitted to the data. We found that EEG data quality was strongly related to demographic characteristics, but not to methodological factors. We were able to replicate maturational, task, and ADHD effects reported in the EEG literature, establishing a link with EEG-landmark effects. Furthermore, we showed that poor data quality significantly increases spectral power beyond effects of maturation and symptom severity. Taken together, the current results indicate that with a careful design and systematic quality control, informative large-scale multicenter trials characterizing neurophysiological mechanisms in neurodevelopmental disorders across the lifespan are feasible. Nevertheless, results are restricted to the limitations reported. Future work will clarify predictive value. KW - electroencephalography (EEG) KW - data quality KW - attention-deficit/hyperactivity disorder (ADHD) KW - artifacts KW - multicenter study Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-228788 SN - 2076-3425 VL - 11 IS - 2 ER - TY - THES A1 - Kipp, Ellen T1 - Therapeutisches Drug Monitoring von Clozapin und Olanzapin bei Kindern und Jugendlichen mit Erkrankungen aus dem schizophrenen Formenkreis T1 - Therapeutic drug monitoring in children and adolescents treated with clozapine and olanzapine for schizophrenic disorders N2 - Derzeit gibt es nur wenige Informationen zu konzentrationsabhängigen klinischen Effekten von Clozapin und Olanzapin in der Behandlung von Kindern und Jugendlichen mit schizophrenen Störungen. Es existieren keine altersspezifisch-definierte therapeutische Zielbereiche für die Höhe der Serumkonzentration in dieser Altersklasse. Das Ziel dieser retrospektiven, naturalistischen Studie ist die Untersuchung der Zusammenhänge zwischen Dosis, Serumkonzentration und klinischen Effekten (Therapieeffekt und unerwünschte Arzneimittelwirkungen) sowie die Untersuchung möglicher Einflussfaktoren darauf. Des Weiteren sollen Erkenntnisse zu therapeutischen Konzentrationsbereichen von Clozapin und Olanzapin bei Kindern und Jugendlichen gewonnen werden. Ausgewertet wurden multizentrische Daten von 32 (Clozapin) bzw. 17 (Olanzapin) Patienten, bei denen routinemäßig Therapeutisches Drug Monitoring im Zeitraum von Februar 2004 bis Dezember 2007 durchgeführt wurde. Die psychopathologische Befundeinschätzung erfolgte mittels der Clinical Global Impression Scale und der Brief Psychiatric Rating Scale, die der unerwünschten Arzneimittelwirkungen mithilfe der Dose Record and Treatment Emergent Symptom Scale bzw. der Udvalg for Kliniske Undersøgelser Side Effect Rating Scale. Bei beiden untersuchten Wirkstoffen zeigte sich eine signifikant positive Korrelation zwischen der (gewichtskorrigierten) Tagesdosis und der Serumkonzentration sowie eine hohe interindividuelle Variabilität der Serumkonzentrationen bei gleicher Dosierung. Als weiterer möglicher Einflussfaktor auf die Höhe der Serumkonzentration konnte in der Olanzapin-Stichprobe eine signifikante Assoziation zwischen dem Geschlecht und der Serumkonzentration nachgewiesen werden: Mädchen scheinen unter gleicher klinischer Dosierung höhere Serumkonzentrationen aufzubauen als Jungen. In beiden Stichproben gab es eine hohe Rate dokumentierter unerwünschter Arzneimittelwirkungen. Ein Zusammenhang zwischen der Höhe der Serumkonzentration und dem Auftreten unerwünschter Arzneimittelwirkungen ließ sich nicht nachweisen. In der Clozapin-Stichprobe zeigte sich ein signifikanter Zusammenhang zwischen der Serumkonzentration und dem Therapieeffekt: Im untersuchten Sample war der Therapieeffekt besser bei niedrigeren (< 350 ng/ml) Serumkonzentrationen. Zudem zeigte sich eine Tendenz zu einem niedrigeren unteren Schwellenwert für einen empfohlenen therapeutischen Bereich der Serumkonzentration verglichen mit dem Bereich der für Erwachsene definiert wurde. In der Olanzapin-Stichprobe ließ sich mit dem gewählten Studiendesign keine signifikante Korrelation zwischen der Serumkonzentration und dem Therapieeffekt nachweisen. Die Mehrheit der pädiatrischen Patienten hatte eine Serumkonzentration innerhalb des empfohlenen Zielbereichs für Erwachsene. Dieses Ergebnis könnte auf eine Übereinstimmung des zu empfehlenden Zielbereichs der Serumkonzentration von Olanzapin in beiden Altersklassen hinweisen. Aufgrund der Limitationen des naturalistischen Studiendesigns sind weitere Studien mit kontrolliertem Design und größerer Stichprobe notwendig, um die Ergebnisse zu replizieren. N2 - There is limited information on the concentration-dependent clinical effects of clozapine and olanzapine in the treatment of children and adolescents with schizophrenic disorders and age-specific therapeutic target ranges of serum concentrations in this age group are not defined yet. The aim of this retrospective, naturalistic study was to investigate the relationship between daily dose, serum concentrations and clinical outcome (positive therapeutic effects and adverse drug reactions) of clozapine and olanzapine in child and adolescents and finally, to investigate any factors influencing these relationships. Furthermore, it should be examined whether the recommended therapeutic concentration ranges for adults are also valid for children and adolescents. Data from 32 (clozapine) and 17 (olanzapine) patients were routinely collected between February 2004 and December 2007. Psychopathological findings were assessed using the Clinical Global Impression Scale and the Brief Psychiatric Rating Scale. Adverse drug reactions were assessed via the Dose Record and Treatment Emergent Symptom Scale and the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale. For both substances investigated, a significant positive correlation was found between the (weight-corrected) daily dose and the serum concentration. Furthermore, a high interindividual variability of the serum concentrations at the same dose was observed. For olanzapine treated individuals, a significant association was found between gender and serum concentration: females were found to have higher serum concentrations than males at the same clinical dose. There was a high rate of documented adverse drug reactions for both substances. However, a correlation between the level of serum concentration and the occurrence of adverse drug reactions could not be demonstrated. In the clozapine sample, there was a significant correlation between the serum concentration and the therapeutic effect: In the investigated sample, the therapeutic effect was better at lower (<350 ng/ml) serum concentrations. In addition, results hint on a lower threshold for a recommended therapeutic range of serum concentration compared to the range defined for adults. In the olanzapine sample, with the selected study design a significant correlation between the serum concentration and the therapeutic effect was not shown. The majority of pediatric patients had serum concentrations within the recommended range for adults. This result hints on concordant recommended serum concentration ranges in both age groups. Due to the limitations of the naturalistic study design, further studies with controlled design and larger sample size are needed to verify and replicate the results. KW - Arzneimittelüberwachung KW - Schizophrenie KW - Clozapin KW - Olanzapin KW - Therapeutisches Drug Monitoring/therapeutic drug monitoring KW - Kinder und Jugendliche/children and adolescents KW - Clozapin/clozapine KW - Olanzapin/olanzapine Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-182699 ER - TY - THES A1 - Klampfl, Karin Maria T1 - Komorbidität bei Kindern und Jugendlichen mit einer Zwangsstörung T1 - Comorbidity in children and adolescents with obsessive-compulsive disorder N2 - Thema der vorliegenden Arbeit war die Erfassung und Beschreibung der psychiatrischen Komorbidität bei Kindern und Jugendlichen mit einer Zwangsstörung. An vier deutschen Universitätskliniken für Kinder- und Jugendpsychiatrie wurden konsekutiv 55 Kinder und Jugendliche mit juveniler Zwangsstörung im Hinblick auf Art und Ausprägung ihrer Zwangssymptomatik sowie hinsichtlich komorbid vorliegender psychiatrischer Störungen mit standardisierten Instrumenten untersucht. Die beschriebene Patientenstichprobe zeigte bezüglich klinischer und epidemiologischer Merkmale große Übereinstimmung mit den bisher epirisch gewonnenen Daten. Es konnte gezeigt werden, dass bei Kindern un Jugendlichen mit Zwangsstörung von einer hohen Zahl komorbider psychischer Störungen auszugehen ist, wobei Angststörungen, affektive Störungen und expansive Störungen (Hyperkinetisches Syndrom, Störung des Sozialverhaltens)am häufigsten zu diagnostizieren waren, gefolgt von Essstörungen und Tics. Die genaue Erhebung des Verteilungsmusters der komorbiden Störungen ist nicht nur von therapeutischer Relevanz, sondern kann auch einen Beitrag leisten, Untergruppen der juvenilen Zwangsstörung zu identifizieren und möglicherweise Rückschlüsse auf die Entstehung der Erkrankung zu ziehen. N2 - To analyze the kind and frequency of psychiatric comorbidity in children and adolescents with obsessive-compulsive disorder (OCD) 55 boys and girls were investigated with standardized instruments at four German university departments of child and adolescent psychiatry. Compared with the epidemiological and clinical features of peadiatric patients of former clinical studies our sample seemed representative. As a result psychiatric comorbidity was very common in both children and adolescents especially with anxiety-disorders, affective disorders and expansive behaviour disorders. Eating disorders and Tics also were found as comorbid conditions of juvenile OCD. The knowledge of these comorbid disorders is not only essential for the treatment it may also help to define subgroups of patients and thus to find out more of the origin and history of the illness. KW - Zwangsstörung KW - Kinder KW - Jugendliche KW - Komorbidität KW - obsessive-compulsive disorder KW - children KW - adolescents KW - psychiatric comorbidity Y1 - 2003 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-8139 ER - TY - THES A1 - Kneer, Katharina Johanna T1 - The association of three anxiety dimensions in children and adolescents: their influence on the brain and malleability by a prevention program T1 - Der Zusammenhang dreier Angstdimensionen bei Kindern und Jugendlichen: ihr Einfluss auf das Gehirn und ihre Veränderbarkeit durch ein Präventionsprogramm N2 - Anxiety disorders are the most prevalent group of neuropsychiatric disorders and go along with high personal suffering. They often arise during childhood and show a progression across the life span, thus making this age a specific vulnerable period during development. Still most research about these disorders is done in adults. In light of this, it seems of utmost importance to identify predictive factors of anxiety disorders in children and adolescents. Temperament or personality traits have been proclaimed as risk markers for the development of subsequent anxiety disorders, but their exact interplay is not clear. In this dissertation an effort is made to contribute to the understanding of how risk markers of early temperamental traits, in this case Trait Anxiety, Anxiety Sensitivity and Separation Anxiety are interplaying. While Trait Anxiety is regarded as a more general tendency to react anxiously to threatening situations or stimuli (Unnewehr, Joormann, Schneider, & Margraf, 1992), Anxiety Sensitivity is the tendency to react with fear to one’s own anxious sensations (Allan et al., 2014; S. Reiss, Peterson, Gursky, & McNally, 1986), and Separation Anxiety is referring to the extent to which the child is avoiding certain situations because of the fear of being separated from primary care givers (In-Albon & Schneider, 2011). In addition, it will be addressed how these measurements are associated with negative life events, as well as brain functioning and if they are malleable by a prevention program in children and adolescents. In study 1 the aim was to extend the knowledge about the interrelations of this anxiety dimensions and negative life events. Results indicated positive correlations of all three anxiety traits as well as with negative life events. Thus, a close connection of all three anxiety measures as well as with negative life events could be indicated. The closest association was found between Anxiety Sensitivity and Trait Anxiety and between Separation Anxiety and Anxiety Sensitivity. Furthermore, negative life events functioned as mediator between Anxiety Sensitivity and Trait Anxiety, indicating that a part of the association was explained by negative life events. In study 2 we extended the findings from study 1 with neurobiological parameters and examined the influence of anxiety traits on emotional brain activation by administering the “emotional face matching task”. This task activated bilateral prefrontal regions as well as both hippocampi and the right amygdala. Further analyses indicated dimension-specific brain activations: Trait Anxiety was associated with a hyperactivation of the left inferior frontal gyrus (IFG) and Separation Anxiety with a lower activation bilaterally in the IFG and the right middle frontal gyrus (MFG). Furthermore, the association between Separation Anxiety and Anxiety Sensitivity was moderated by bi-hemispheric Separation-Anxiety-related IFG activation. Thus, we could identify distinct brain activation patterns for the anxiety dimensions (Trait Anxiety and Separation Anxiety) and their associations (Separation Anxiety and Anxiety Sensitivity). The aim of study 3 was to probe the selective malleability of the anxiety dimensions via a prevention program in an at-risk population. We could identify a reduction of all three anxiety traits from pre- to post-prevention-assessment and that this effect was significant in Anxiety Sensitivity and Trait Anxiety scores. Furthermore, we found that pre-intervention Separation Anxiety and Anxiety Sensitivity post-intervention were associated. In addition, pre-interventive scores were correlated with the intervention-induced change within the measure (i.e., the higher the score before the intervention the higher the prevention-induced change) and pre-intervention Anxiety Sensitivity correlated with the change in Separation Anxiety scores. All relations, seemed to be direct, as mediation/moderation analyses with negative life events did not reveal any significant effect. These results are very promising, because research about anxiety prevention in children and adolescents is still rare and our results are indicating that cognitive-behavioural-therapy based prevention is gilding significant results in an indicated sample even when samples sizes are small like in our study. In sum the present findings hint towards distinct mechanisms underlying the three different anxiety dimensions on a phenomenological and neurobiological level, though they are highly overlapping (Higa-McMillan, Francis, Rith-Najarian, & Chorpita, 2016; Taylor, 1998). Furthermore, the closest associations were found between Anxiety Sensitivity and Trait Anxiety, as well as between Separation Anxiety and Anxiety Sensitivity. Specifically, we were able to find a neuronal manifestation of the association between Separation Anxiety and Anxiety Sensitivity (Separation Anxiety-specific IFG activation) and a predictive potential on prevention influence. The results of these studies lead to a better understanding of the etiology of anxiety disorders and the interplay between different anxiety-related temperamental traits and could lead to further valuable knowledge about the intervention as well as further prevention strategies. N2 - Angststörungen sind die am häufigsten auftretende Gruppe neuropsychiatrischer Erkrankungen und führen in vielen Fällen zu großem Leid. Sie beginnen häufig in der Kindheit und Spontanremissionen sind selten, im Gegenteil - die Erkrankungen verschlimmern sich häufig und führen zu weiteren psychischen Erkrankungen. Dabei stellt die Kindheit eine Lebensphase mit besonderer Vulnerabilität für die Entwicklung von Angsterkrankungen dar. Trotzdem werden die meisten Studien zu Angststörungen weiterhin mit Erwachsenen durchgeführt. Vor diesem Hintergrund scheint es von größter Bedeutung, prädiktive Faktoren für Angststörungen bei Kindern und Jugendlichen zu identifizieren. Temperament- oder Persönlichkeitsmerkmale werden als Risikomarker für Angststörungen gesehen. Dabei ist das genaue Zusammenspiel dieser Risikomarker im Kindes- und Jugendalter nicht klar. Diese Dissertation leistet dabei einen Beitrag zum Verständnis des Zusammenspiels der Risikomarker Trait-Angst, Angstsensitivität und Trennungsangst. Während Trait-Angst als eine eher allgemeinere Tendenz angesehen wird, ängstlich auf bedrohliche Situationen oder Reize zu reagieren (Unnewehr et al., 1992), ist Angstsensitivität die Tendenz, mit Angst auf die eigenen potentiell angst-assoziierten Empfindungen zu reagieren (Allan et al., 2014; S. Reiss et al., 1986). Trennungsangst bezieht sich auf das Ausmaß, in dem das Kind bestimmt Situationen vermeidet, weil es befürchtet von Primärbezugspersonen getrennt zu werden (In-Albon & Schneider, 2011). Darüber hinaus befasst sich diese Dissertation damit, wie diese drei Angstmaße mit negativen Lebensereignissen und Gehirnaktivierung zusammenhängen und evaluiert deren Veränderbarkeit durch ein indiziertes Präventionsprogram. Zu diesem Zweck wurden drei Studien durchgeführt. In Studie 1 war das Ziel, das Wissen, um die Wechselbeziehungen dieser Angstmaße und negativer Lebensereignisse zu erweitern. Die Ergebnisse zeigten enge Zusammenhänge zwischen den drei Angstmaßen und ebenso mit der Anzahl negativer Lebensereignissen. Darüber hinaus fungierten negative Lebensereignisse als Mediator zwischen Angstsensitivität und Trait-Angst, was darauf hinweist, dass ein Teil des Zusammenhangs dieser beiden Angstmaße durch negative Lebensereignisse erklärt wird. In Studie 2 erweiterten wir die Ergebnisse aus Studie 1 um ein neurobiologisches Maß und untersuchten den Einfluss der Angstmaße auf Hirnaktivierung während emotionaler Verarbeitung mittels der Durchführung des „emotional face matching task“. Die Analyse zeigte eine Aktivierung während der Aufgabe in bilateralen präfrontalen Regionen sowie beiden Hippocampi und der rechten Amygdala. Angstspezifische Aktivierungen zeigten eine Trait-Angst-spezifische Hyperaktivierung im linken gyrus frontalis inferior (IFG) und eine Trennungsangst-spezifische Hypoaktivierung in beiden IFG und dem rechten gyrus frontalis medius. Darüber hinaus wurde der Zusammenhang zwischen Trennungsangst und Angstsensitivität durch bi-hemisphärische Trennungsangst-spezifische IFG Aktivierung moderiert. Wir konnten also Hirnregionen identifizieren, die spezifisch mit den Angstmaßen assoziiert waren (Trait-Angst und Trennungsangst) und auch deren Verbindung moderierten (Trennungsangst und Angstsensitivität). Ziel der Studie 3 war es, die Veränderbarkeit der Angstmaße anhand eines Präventionsprogramms in einer Risikopopulation zu untersuchen. Wir konnten eine Verringerung aller drei Angstmaße durch die Prävention feststellen und dieser Effekt war für Angstsensitivität und Trait-Angst statistisch signifikant. Darüber hinaus konnten wir zeigen, dass die Trennungsangst vor der Prävention signifikant mit der Angstsensitivität nach der Prävention korrelierte. Zusätzlich sagte das Ausmaß der Angstmaße vor der Prävention die durch die Intervention induzierten Veränderung innerhalb eines Maßes signifikant voraus (Je höher die Werte vor der Intervention, desto höher die präventionsinduzierte Änderung), zudem vermochte Angstsensitivität vor der Intervention Änderung der Trennungsangstwerte zu prognostizierten. Alle gefunden Zusammenhänge schienen darüber hinaus direkt zu sein, da Mediations- / Moderationsanalysen mit negativen Lebensereignissen keinen signifikanten Effekt zeigten. Diese Ergebnisse sind sehr vielversprechend, da es nur wenig Forschung zur Angstprävention bei Kindern und Jugendlichen gibt und unsere Ergebnisse darauf hinweisen das Präventionsprogramme, welche auf Kognitiv-verhaltenstherapeutischen Elementen beruhen in einer indizierten Population gute Effekte erzielen können, selbst wenn es sich, wie in unserem Fall, um eine kleine Stichprobengröße handelt. Zusammenfassend deuten die vorliegenden Ergebnisse auf unterschiedliche Mechanismen hin, die den drei verschiedenen Angstmaßen auf phänomenologischer und neurobiologischer Ebene zugrunde liegen. Darüber hinaus wurden enge Assoziationen zwischen Angstsensitivität und Trait-Angst sowie Trennungsangst und Angstsensitivität gefunden. Insbesondere konnten wir eine neuronale Manifestation des Zusammenhangs zwischen Trennungsangst und Angstsensitivität (Trennungangstspezifische IFG-Aktivierung) und ein Vorhersagepotential für den Einfluss der Prävention finden. Die Resultate der beschriebenen Studien tragen zu einem besseren Verständnis der Ätiologie von Angststörungen und dem Zusammenspiel verschiedener angstspezifischer Temperamentmerkmale bei, und können zu weiteren wertvollen Erkenntnissen über Interventions- sowie Präventionsstrategien führen. KW - Prävention KW - Angst KW - Kind KW - Jugend KW - Angsterkrankungen KW - Kindheit und Jugend KW - Angst als Eigenschaft Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-257468 ER - TY - JOUR A1 - Kolar, David R. A1 - Hammerle, Florian A1 - Jenetzky, Ekkehart A1 - Huss, Michael A1 - Bürger, Arne T1 - Aversive tension in female adolescents with Anorexia Nervosa: a controlled ecological momentary assessment using smartphones JF - BMC Psychiatry N2 - Background Current models of Anorexia Nervosa (AN) emphasize the role of emotion regulation. Aversive tension, described as a state of intense arousal and negative valence, is considered to be a link between emotional events and disordered eating. Recent research focused only on adult patients, and mainly general emotion regulation traits were studied. However, the momentary occurrence of aversive tension, particularly in adolescents with AN, has not been previously studied. Method 20 female adolescents with AN in outpatient treatment and 20 healthy adolescents aged 12 to 19 years participated in an ecological momentary assessment using their smartphones. Current states of aversive tension and events were assessed hourly for two consecutive weekdays. Mean and maximum values of aversive tension were compared. Multilevel analyses were computed to test the influence of time and reported events on aversive tension. The effect of reported events on subsequent changes of aversive tension in patients with AN were additionally tested in a multilevel model. Results AN patients showed higher mean and maximum levels of aversive tension. In a multilevel model, reported food intake was associated with higher levels of aversive tension in the AN group, whereas reported school or sport-related events were not linked to specific states of aversive tension. After food intake, subsequent increases of aversive tension were diminished and decreases of aversive tension were induced in adolescents with AN. Conclusions Aversive tension may play a substantial role in the psychopathology of AN, particular in relation with food intake. Therefore, treatment should consider aversive tension as a possible intervening variable during refeeding. Our findings encourage further research on aversive tension and its link to disordered eating. KW - Anorexia nervosa KW - Adolescence KW - Aversive tension KW - Ecological momentary assessment KW - Emotion regulation KW - Eating disorder KW - Smartphones Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-164720 VL - 16 IS - 97 ER - TY - JOUR A1 - Kuhlmann, S.M. A1 - Huss, M. A1 - Bürger, A. A1 - Hammerle, F. T1 - Coping with stress in medical students: results of a randomized controlled trial using a mindfulness-based stress prevention training (MediMind) in Germany JF - BMC Medical Education N2 - Background High prevalence rates of psychological distress in medical training and later professional life indicate a need for prevention. Different types of intervention were shown to have good effects, but little is known about the relative efficacy of different types of stress management interventions, and methodological limitations have been reported. In order to overcome some of these limitations, the present study aimed at evaluating the effect of a specifically developed mindfulness-based stress prevention training for medical students (MediMind) on measures of distress, coping and psychological morbidity. Methods We report on a prospective randomized controlled trial with three study conditions: experimental treatment (MediMind), standard treatment (Autogenic Training) and a control group without treatment. The sample consisted of medical or dental students in the second or eighth semester. They completed self-report questionnaires at baseline, after the training and at one year follow-up. Distress (Trier Inventory for the Assessment of Chronic Stress, TICS) was assessed as the primary outcome and coping (Brief COPE) as a co-primary outcome. Effects on the psychological morbidity (Brief Symptom Inventory, BSI) as a secondary outcome were expected one year after the trainings. Results Initially, N = 183 students were randomly allocated to the study groups. At one year follow-up N = 80 could be included into the per-protocol analysis: MediMind (n =31), Autogenic Training (n = 32) and control group (n = 17). A selective drop-out for students who suffered more often from psychological symptoms was detected (p = .020). MANCOVA’s on TICS and Brief COPE revealed no significant interaction effects. On the BSI, a significant overall interaction effect became apparent (p = .002, η2partial = .382), but post hoc analyses were not significant. Means of the Global Severity Index (BSI) indicated that MediMind may contribute to a decrease in psychological morbidity. Conclusion Due to the high and selective dropout rates, the results cannot be generalized and further research is necessary. Since the participation rate of the trainings was high, a need for further prevention programs is indicated. The study gives important suggestions on further implementation and evaluation of stress prevention in medical schools. KW - Medical students KW - Distress KW - Stress KW - Stress prevention KW - Mindfulness Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-164593 VL - 16 ER - TY - JOUR A1 - Kuhn, Manuel A1 - Scharfenort, Robert A1 - Schümann, Dirk A1 - Schiele, Miriam A. A1 - Münsterkötter, Anna L. A1 - Deckert, Jürgen A1 - Domschke, Katharina A1 - Haaker, Jan A1 - Kalisch, Raffael A1 - Pauli, Paul A1 - Reif, Andreas A1 - Romanos, Marcel A1 - Zwanzger, Peter A1 - Lonsdorf, Tina B. T1 - Mismatch or allostatic load? Timing of life adversity differentially shapes gray matter volume and anxious temperament JF - Social Cognitive and Affective Neuroscience N2 - Traditionally, adversity was defined as the accumulation of environmental events (allostatic load). Recently however, a mismatch between the early and the later (adult) environment (mismatch) has been hypothesized to be critical for disease development, a hypothesis that has not yet been tested explicitly in humans. We explored the impact of timing of life adversity (childhood and past year) on anxiety and depression levels (N = 833) and brain morphology (N = 129). Both remote (childhood) and proximal (recent) adversities were differentially mirrored in morphometric changes in areas critically involved in emotional processing (i.e. amygdala/hippocampus, dorsal anterior cingulate cortex, respectively). The effect of adversity on affect acted in an additive way with no evidence for interactions (mismatch). Structural equation modeling demonstrated a direct effect of adversity on morphometric estimates and anxiety/depression without evidence of brain morphology functioning as a mediator. Our results highlight that adversity manifests as pronounced changes in brain morphometric and affective temperament even though these seem to represent distinct mechanistic pathways. A major goal of future studies should be to define critical time periods for the impact of adversity and strategies for intervening to prevent or reverse the effects of adverse childhood life experiences. KW - VBM KW - childhood maltreatment KW - adversity KW - stressful life events KW - mismatch KW - allostatic load Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-189645 VL - 11 IS - 4 ER - TY - THES A1 - Kämpf, Anne Kristina T1 - Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder? T1 - Zytogenetische Veränderungen durch Methylphenidat bei Kindern mit ADHS? N2 - MPH wird seit über 50 Jahren zur Therapie des ADHS eingesetzt. Gerade in den letzten Jahren wurde deutlich, dass der Einsatz ohne fundierte Kenntnis über mögliche Langzeit-effekte erfolgte, da zum Zeitpunkt der Zulassung aufgrund der begrenzten technischen Möglichkeiten weniger strenge und weniger umfassende Einschränkungen beachtet wer-den mussten (Walitza, Werner et al. 2007). Da in den letzten Jahren die Anzahl der verschrieben Tagesdosen MPH sprunghaft anstiegen, ist es wichtig, auch die langfristigen Nebenwirkungen von MPH zu untersuchen (Janhsen 2007). Eine Studie von El-Zein et al. von 2005 brachte die Frage auf, ob MPH eventuell Genomschäden hervorrufe. Bei 11 von 12 untersuchten Kindern wurde unter der Therapie mit MPH um das 2,4fache erhöhte Mikrokernfrequenzen gefunden (El-Zein, Abdel-Rahman et al. 2005). Dies beunruhig-te vor allem im Hinblick auf das mit erhöhten Mikrokernfrequenzen korrelierte erhöhte Karzinomrisiko. Eine daraufhin von Walitza et al. durchgeführte Studie, die ebenfalls Mikrokernfrequenzen in peripheren Blutzellen untersuchte (Walitza, Werner et al. 2007), konnte keine Hinweise auf eine Genomschädigung durch MPH erbringen. Zahlreiche weitere Untersuchungen zur potentiellen Genomschädigung durch MPH konnten die Ergebnisse durch in vivo- oder in vitro-Studien nicht bestätigen und kritisierten die ge-ringe Stichprobengröße sowie mangelnde Transparenz der Arbeit von El-Zein (Preston, Kollins et al. 2005; El-Zein, Hay et al. 2006; Holtmann, Kaina et al. 2006; Suter, Martus et al. 2006). Da jedoch keine weitere Studie sich konkret mit zytogenetischen Effekten in peripheren Blutzellen befasste, soll die vorliegende Arbeit dazu dienen, den Verdacht einer Genomschädigung endgültig auszuräumen (Walitza, Kampf et al. 2009). Dazu wurde eine größere Gruppe von Kindern eingeschlossen, sowie Untersuchungen zu verschiedenen Zeitpunkten während der MPH-Einnahme, bis hin zu Untersuchungen nach einem Zeitraum von 12 Monaten der MPH- Einnahme, durchgeführt. Mit Hilfe eines Mikrokerntestes wurden in der vorliegenden Studie versucht, DNS-Schäden an periphe-ren Lymphozyten zu bestimmen, um daraus auf ein potentiell erhöhtes Krebsrisiko schließen zu können. Im Vergleich mit einer gesunden Kontrollgruppe waren die Werte von ADHS-Kindern ohne MPH-Therapie sowie nach 3 und 12 Monaten MPH-Therapie zwar signifikant er-höht, diese gesunde Kontrollgruppe wies jedoch im Vergleich mit internationalen Refe-renzwerten eine extrem niedrige Mikrokernfrequenz auf, so dass davon ausgegangen werden muss, dass diese Vergleiche nur begrenzte Aussagekraft haben. In keiner der verschiedenen mit MPH therapierten Gruppen konnten über die Dauer der Einnahme eine signifikant Erhöhung der Mikrokernfrequenzen im Vergleich zu den Werten vor Einnahmebeginn nachgewiesen werden, was den Schluss zulässt, dass eine Therapie mit Methylphenidat in therapieüblichen Dosen bei Kindern das Erbgut nicht zu schädigen scheint. Dieses Ergebnis bestätigen inzwischen auch weitere Studien. Der Mikrokerntest erfasst Genomschäden, nicht jedoch etwaige tumorpromovierende Eigenschaften des verabreichten Medikaments. Damit ist unklar, ob MPH auf andere Art als über eine Schädigung des Genoms das Karzinomrisiko erhöhen könnte. Erste epidemiologische Studien sehen jedoch keinen Hinweis auf eine wie auch immer entstandene erhöhte Karzinominzidenz unter der Therapie mit MPH (Selby, Friedman et al. 1989; Oestreicher, Friedman et al. 2007). Hier scheinen jedoch weitere epidemiologische Studien, die mög-lichst große Zeitspannen umfassen, nötig zu sein N2 - Attention-deficit/hyperactivity disorder (ADHD) is the most frequent psychiatric disorder in children and adolescents and is often treated with methylphenidate (MPH), resulting in MPH exposure in more than 1% of all children in many countries. A 2005 report on cytogenetic effects in peripheral lymphocytes from 12 ADHD children treated for 3 months with MPH raised questions about its genetic toxicity and potential carcinogenicity. A healthy control group (23 individuals), a chronically MPH-treated (>12 months) group (21 patients), and a drug naïve group of ADHD-affected children (26 patients), which was analyzed again after 3 months (17 patients) and 6 months (11 patients), provided samples for analysis of micronucleated lymphocytes. No significant alteration in genomic damage as seen as micronucleus frequency in peripheral lypmphocytes was detected after MPH treatment. No indication for genomic damage induced by MPH was obtained in this study. Ongoing studies in the USA, as well as continuation of recently published epidemiological cancer incidence analysis should provide additional reassurance for MPH-treated ADHD patients. KW - Methylphenidat KW - Aufmerksamkeits-Defizit-Syndrom KW - Kleinkern KW - micronucleus assay KW - cytogenetic effects KW - mutagenicity Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-77652 ER - TY - JOUR A1 - Lechermeier, Carina G. A1 - Zimmer, Frederic A1 - Lüffe, Teresa M. A1 - Lesch, Klaus-Peter A1 - Romanos, Marcel A1 - Lillesaar, Christina A1 - Drepper, Carsten T1 - Transcript analysis of zebrafish GLUT3 genes, slc2a3a and slc2a3b, define overlapping as well as distinct expression domains in the zebrafish (Danio rerio) central nervous system JF - Frontiers in Molecular Neuroscience N2 - The transport of glucose across the cell plasma membrane is vital to most mammalian cells. The glucose transporter (GLUT; also called SLC2A) family of transmembrane solute carriers is responsible for this function in vivo. GLUT proteins encompass 14 different isoforms in humans with different cell type-specific expression patterns and activities. Central to glucose utilization and delivery in the brain is the neuronally expressed GLUT3. Recent research has shown an involvement of GLUT3 genetic variation or altered expression in several different brain disorders, including Huntington’s and Alzheimer’s diseases. Furthermore, GLUT3 was identified as a potential risk gene for multiple psychiatric disorders. To study the role of GLUT3 in brain function and disease a more detailed knowledge of its expression in model organisms is needed. Zebrafish (Danio rerio) has in recent years gained popularity as a model organism for brain research and is now well-established for modeling psychiatric disorders. Here, we have analyzed the sequence of GLUT3 orthologs and identified two paralogous genes in the zebrafish, slc2a3a and slc2a3b. Interestingly, the Glut3b protein sequence contains a unique stretch of amino acids, which may be important for functional regulation. The slc2a3a transcript is detectable in the central nervous system including distinct cellular populations in telencephalon, diencephalon, mesencephalon and rhombencephalon at embryonic and larval stages. Conversely, the slc2a3b transcript shows a rather diffuse expression pattern at different embryonic stages and brain regions. Expression of slc2a3a is maintained in the adult brain and is found in the telencephalon, diencephalon, mesencephalon, cerebellum and medulla oblongata. The slc2a3b transcripts are present in overlapping as well as distinct regions compared to slc2a3a. Double in situ hybridizations were used to demonstrate that slc2a3a is expressed by some GABAergic neurons at embryonic stages. This detailed description of zebrafish slc2a3a and slc2a3b expression at developmental and adult stages paves the way for further investigations of normal GLUT3 function and its role in brain disorders. KW - glucose transporter KW - nervous system KW - brain disorders KW - psychiatric disorders KW - brain development KW - GABA KW - GAD1 Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201797 VL - 12 IS - 199 ER - TY - JOUR A1 - Ludwig, K. U. A1 - Sämann, P. A1 - Alexander, M. A1 - Becker, J. A1 - Bruder, J. A1 - Moll, K. A1 - Spieler, D. A1 - Czisch, M. A1 - Warnke, A. A1 - Docherty, S. J. A1 - Davis, O. S. P. A1 - Plomin, R. A1 - Nöthen, M. M. A1 - Landerl, K. A1 - Müller-Myhsok, B. A1 - Hoffmann, P. A1 - Schumacher, J. A1 - Schulte-Körne, G. A1 - Czamara, D. T1 - A common variant in Myosin-18B contributes to mathematical abilities in children with dyslexia and intraparietal sulcus variability in adults JF - Translational Psychiatry N2 - The ability to perform mathematical tasks is required in everyday life. Although heritability estimates suggest a genetic contribution, no previous study has conclusively identified a genetic risk variant for mathematical performance. Research has shown that the prevalence of mathematical disabilities is increased in children with dyslexia. We therefore correlated genome-wide data of 200 German children with spelling disability, with available quantitative data on mathematic ability. Replication of the top findings in additional dyslexia samples revealed that rs133885 was a genome-wide significant marker for mathematical abilities\((P_{comb}=7.71 x 10^{-10}, n=699)\), with an effect size of 4.87%. This association was also found in a sample from the general population (P=0.048, n=1080), albeit with a lower effect size. The identified variant encodes an amino-acid substitution in MYO18B, a protein with as yet unknown functions in the brain. As areas of the parietal cortex, in particular the intraparietal sulcus (IPS), are involved in numerical processing in humans, we investigated whether rs133885 was associated with IPS morphology using structural magnetic resonance imaging data from 79 neuropsychiatrically healthy adults. Carriers of the MYO18B risk-genotype displayed a significantly lower depth of the right IPS. This validates the identified association between rs133885 and mathematical disability at the level of a specific intermediate phenotype. KW - disability KW - sulcal morphology KW - prelevance KW - identification KW - brain KW - cancer KW - association KW - developmental dyscalculia KW - tumor-suppressor gene KW - correlate KW - disorders KW - dyscalculia KW - dyslexia KW - genomic imaging KW - mathematics KW - quantitative trait Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-131513 N1 - Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp). VL - 3 IS - e229 ER - TY - THES A1 - López de Miguel, Pilar T1 - Patientenzufriedenheit mit dem Aufklärungsgespräch T1 - Patient satisfaction with informed consent N2 - Ziele: Das Ziel der vorliegenden Arbeit ist eine standardisierte Analyse der Patientenzufriedenheit mit dem Aufklärungsgespräch und die mögliche Einflussfaktoren, die hier eine Rolle spielen können, zu bieten. Methodik: Es wurden 189 Fragebögen bzw. Aufklärungsgespräche in den Kliniken für Anästhesie und Innere Medizin im St. Josef Krankenhaus und Chirurgie und Kinder- und Jugendpsychiatrie im Leopoldina Krankenhaus in Schweinfurt untersucht. Ergebnisse: Der Fragebogen, der verwendet wurde, war reliabel. Es zeigte sich eine schlechte Item-Selektivität. Die Kriteriumsvalidität konnte bestätigt werden jedoch nicht die diskriminante Validität. Die Patienten waren zufriedener mit Ärzten, die Deutsch als Muttersprache angaben, mit längeren Aufklärungsgesprächen und mit Fachärzten im Vergleich zu Assistenzärzten. Eine höhere allgemeine Lebenszufriedenheit war mit höherer Patientenzufriedenheit mit dem Aufklärungsgespräch assoziiert. Der moralistische Bias kann einen Störfaktor der Validität der Messungen darstellen. Zusammenfassung: Eine angemessene Gesprächdauer, die deutsche Muttersprache und der Facharztstatus des aufklärenden Arztes haben einen positiven Einfluss auf die Patientenzufriedenheit mit dem Aufklärungsgespräch. Um sicher zu stellen, welche von diesen drei Faktoren besondere Wichtigkeit besitzt, werden weitere Untersuchungen benötigt. N2 - Objective: The aim of the present study is to provide a standardized analysis of patient satisfaction with informed consent process and the possible influencing factors that can play a role here. Methoden: 189 questionnaires/informed consent were examined in the clinics for anesthesia and internal medicine in St. Josef Hospital and surgery and child and adolescent psychiatry in Leopoldina Hospital in Schweinfurt. Results: The questionnaire used was reliable. There was poor item selectivity. The criterion validity was confirmed but not the discriminant validity. Patients were more satisfied with doctors who spoke German as their native language, with longer duration oft the informed consent process and with specialists compared to assistant doctors. Higher general life satisfaction was associated with higher patient satisfaction. The moralistic bias can represent a confounding factor in the validity of the measurements. Conclusion: An appropriate duration of the conversation, the German native language and the doctor's specialist status have a positive influence on patient satisfaction with informed consent process. Further research is needed to determine which of these three factors is particularly important. KW - Zufriedenheit KW - Patientenzufriedenheit KW - Informed consent KW - Aufklärung KW - Aufklärungsgespräch KW - Satisfaction Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-347201 ER - TY - JOUR A1 - Lüffe, Teresa M. A1 - Bauer, Moritz A1 - Gioga, Zoi A1 - Özbay, Duru A1 - Romanos, Marcel A1 - Lillesaar, Christina A1 - Drepper, Carsten T1 - Loss-of-Function Models of the Metabotropic Glutamate Receptor Genes Grm8a and Grm8b Display Distinct Behavioral Phenotypes in Zebrafish Larvae (Danio rerio) JF - Frontiers in Molecular Neuroscience N2 - Members of the family of metabotropic glutamate receptors are involved in the pathomechanism of several disorders of the nervous system. Besides the well-investigated function of dysfunctional glutamate receptor signaling in neurodegenerative diseases, neurodevelopmental disorders (NDD), like autism spectrum disorders (ASD) and attention-deficit and hyperactivity disorder (ADHD) might also be partly caused by disturbed glutamate signaling during development. However, the underlying mechanism of the type III metabotropic glutamate receptor 8 (mGluR8 or GRM8) involvement in neurodevelopment and disease mechanism is largely unknown. Here we show that the expression pattern of the two orthologs of human GRM8, grm8a and grm8b, have evolved partially distinct expression patterns in the brain of zebrafish (Danio rerio), especially at adult stages, suggesting sub-functionalization of these two genes during evolution. Using double in situ hybridization staining in the developing brain we demonstrate that grm8a is expressed in a subset of gad1a-positive cells, pointing towards glutamatergic modulation of GABAergic signaling. Building on this result we generated loss-of-function models of both genes using CRISPR/Cas9. Both mutant lines are viable and display no obvious gross morphological phenotypes making them suitable for further analysis. Initial behavioral characterization revealed distinct phenotypes in larvae. Whereas grm8a mutant animals display reduced swimming velocity, grm8b mutant animals show increased thigmotaxis behavior, suggesting an anxiety-like phenotype. We anticipate that our two novel metabotropic glutamate receptor 8 zebrafish models may contribute to a deeper understanding of its function in normal development and its role in the pathomechanism of disorders of the central nervous system. KW - nervous system KW - brain disorders KW - psychiatric disorders KW - brain development KW - excitatory/inhibitory imbalance KW - metabotropic glutamate (mGlu) receptor Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-277429 SN - 1662-5099 VL - 15 ER - TY - JOUR A1 - Lüffe, Teresa M. A1 - D'Orazio, Andrea A1 - Bauer, Moritz A1 - Gioga, Zoi A1 - Schoeffler, Victoria A1 - Lesch, Klaus-Peter A1 - Romanos, Marcel A1 - Drepper, Carsten A1 - Lillesaar, Christina T1 - Increased locomotor activity via regulation of GABAergic signalling in foxp2 mutant zebrafish – implications for neurodevelopmental disorders JF - Translational Psychiatry N2 - Recent advances in the genetics of neurodevelopmental disorders (NDDs) have identified the transcription factor FOXP2 as one of numerous risk genes, e.g. in autism spectrum disorders (ASD) and attention-deficit/hyperactivity disorder (ADHD). FOXP2 function is suggested to be involved in GABAergic signalling and numerous studies demonstrate that GABAergic function is altered in NDDs, thus disrupting the excitation/inhibition balance. Interestingly, GABAergic signalling components, including glutamate-decarboxylase 1 (Gad1) and GABA receptors, are putative transcriptional targets of FOXP2. However, the specific role of FOXP2 in the pathomechanism of NDDs remains elusive. Here we test the hypothesis that Foxp2 affects behavioural dimensions via GABAergic signalling using zebrafish as model organism. We demonstrate that foxp2 is expressed by a subset of GABAergic neurons located in brain regions involved in motor functions, including the subpallium, posterior tuberculum, thalamus and medulla oblongata. Using CRISPR/Cas9 gene-editing we generated a novel foxp2 zebrafish loss-of-function mutant that exhibits increased locomotor activity. Further, genetic and/or pharmacological disruption of Gad1 or GABA-A receptors causes increased locomotor activity, resembling the phenotype of foxp2 mutants. Application of muscimol, a GABA-A receptor agonist, rescues the hyperactive phenotype induced by the foxp2 loss-of-function. By reverse translation of the therapeutic effect on hyperactive behaviour exerted by methylphenidate, we note that application of methylphenidate evokes different responses in wildtype compared to foxp2 or gad1b loss-of-function animals. Together, our findings support the hypothesis that foxp2 regulates locomotor activity via GABAergic signalling. This provides one targetable mechanism, which may contribute to behavioural phenotypes commonly observed in NDDs. KW - comparative genomics KW - molecular neuroscience Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-264713 VL - 11 ER - TY - THES A1 - Lüffe, Teresa Magdalena T1 - Behavioral and pharmacological validation of genetic zebrafish models for ADHD T1 - Pharmakologische und verhaltensbasierte Validierung genetischer Zebrafischmodelle für ADHS N2 - Attention-deficit/hyperactivity disorder (ADHD) is the most prevalent neurodevelopmental disorder described in psychiatry today. ADHD arises during early childhood and is characterized by an age-inappropriate level of inattention, hyperactivity, impulsivity, and partially emotional dysregulation. Besides, substantial psychiatric comorbidity further broadens the symptomatic spectrum. Despite advances in ADHD research by genetic- and imaging studies, the etiopathogenesis of ADHD remains largely unclear. Twin studies suggest a heritability of 70-80 % that, based on genome-wide investigations, is assumed to be polygenic and a mixed composite of small and large, common and rare genetic variants. In recent years the number of genetic risk candidates is continuously increased. However, for most, a biological link to neuropathology and symptomatology of the patient is still missing. Uncovering this link is vital for a better understanding of the disorder, the identification of new treatment targets, and therefore the development of a more targeted and possibly personalized therapy. The present thesis addresses the issue for the ADHD risk candidates GRM8, FOXP2, and GAD1. By establishing loss of function zebrafish models, using CRISPR/Cas9 derived mutagenesis and antisense oligonucleotides, and studying them for morphological, functional, and behavioral alterations, it provides novel insights into the candidate's contribution to neuropathology and ADHD associated phenotypes. Using locomotor activity as behavioral read-out, the present work identified a genetic and functional implication of Grm8a, Grm8b, Foxp2, and Gad1b in ADHD associated hyperactivity. Further, it provides substantial evidence that the function of Grm8a, Grm8b, Foxp2, and Gad1b in activity regulation involves GABAergic signaling. Preliminary indications suggest that the three candidates interfere with GABAergic signaling in the ventral forebrain/striatum. However, according to present and previous data, via different biological mechanisms such as GABA synthesis, transmitter release regulation, synapse formation and/or transcriptional regulation of synaptic components. Intriguingly, this work further demonstrates that the activity regulating circuit, affected upon Foxp2 and Gad1b loss of function, is involved in the therapeutic effect mechanism of methylphenidate. Altogether, the present thesis identified altered GABAergic signaling in activity regulating circuits in, presumably, the ventral forebrain as neuropathological underpinning of ADHD associated hyperactivity. Further, it demonstrates altered GABAergic signaling as mechanistic link between the genetic disruption of Grm8a, Grm8b, Foxp2, and Gad1b and ADHD symptomatology like hyperactivity. Thus, this thesis highlights GABAergic signaling in activity regulating circuits and, in this context, Grm8a, Grm8b, Foxp2, and Gad1b as exciting targets for future investigations on ADHD etiopathogenesis and the development of novel therapeutic interventions for ADHD related hyperactivity. Additionally, thigmotaxis measurements suggest Grm8a, Grm8b, and Gad1b as interesting candidates for prospective studies on comorbid anxiety in ADHD. Furthermore, expression analysis in foxp2 mutants demonstrates Foxp2 as regulator of ADHD associated gene sets and neurodevelopmental disorder (NDD) overarching genetic and functional networks with possible implications for ADHD polygenicity and comorbidity. Finally, with the characterization of gene expression patterns and the generation and validation of genetic zebrafish models for Grm8a, Grm8b, Foxp2, and Gad1b, the present thesis laid the groundwork for future research efforts, for instance, the identification of the functional circuit(s) and biological mechanism(s) by which Grm8a, Grm8b, Foxp2, and Gad1b loss of function interfere with GABAergic signaling and ultimately induce hyperactivity. N2 - Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) ist mit einer weltweiten Prävalenz von rund 5 % die am häufigsten vorkommende Neuroentwicklungsstörung. Das Krankheitsbild, das zumeist im Kindesalter auftritt und bis ins Erwachsenenalter bestehen kann, zeigt sich im Wesentlichen durch eine Beeinträchtigung der Aufmerksamkeit, der Aktivität, der Impuls-kontrolle und zum Teil durch emotionale Dysregulation. Darüber hinaus führt das vermehrte Auftreten von psychischen Begleiterkrankungen (so genannte Komorbiditäten) zu einer komplexen Symptomatik vieler Betroffener, die über die klassischen Merkmale von ADHS hinausgeht. Während das Krankheitsbild vielfach beschrieben wurde, ist die Ätiopathogenese trotz intensiver wissenschaftlicher Bemühungen bis heute weitestgehend ungeklärt. Zwillingsstudien weisen darauf hin, dass ADHS zu 70-80 % erblich bedingt ist. Aufgrund mehrerer Genom-Studien wird vermutet, dass es sich dabei um eine polygene Vererbbarkeit handelt und sowohl kleine (SNPs), verhältnismäßig häufig auftretende, als auch große (CNVs) verhältnismäßig seltene Genpolymorphismen beteiligt sind. Die Anzahl der potenziellen Risikogene für ADHS ist in den letzten Jahren kontinuierlich gestiegen, jedoch ist es nach wie vor unklar, inwiefern und durch welche biologischen Prozesse die meisten zur Neuropathologie und Symptomatik von ADHS Patienten beitragen. Diese Prozesse zu identifizieren ist von zentraler Bedeutung für ein besseres Verständnis der Erkrankung, der Identifizierung neuer Angriffsziele und somit, der Entwicklung gezielterer und möglicherweise personalisierter Behandlungsmöglichkeiten. Die vorliegende Arbeit befasst sich mit diesen Prozessen am Beispiel der potenziellen Risikogene GRM8, FOXP2 und GAD1. Durch die Etablierung und Validierung entsprechender (geneti-scher) Knockout und Knockdown Zebrafischmodelle und der anschließenden Untersuchung auf Verhaltens-, morphologische und funktionelle Veränderungen liefert die vorliegende Dissertation wichtige Erkenntnisse über die funktionelle Relevanz der einzelnen Kandidaten für die Neuropathologie und die Symptomatik von ADHS. Beispielsweise zeigen die erfassten Aktivitätsdaten von Knockdown und Knockout Larven, dass Grm8a, Grm8b, Foxp2 und Gad1b an der Regulation von Bewegungsaktivität beteiligt sind und dass dies, die korrekte Funktion GABAerger Prozesse bedarf. Des Weiteren liefert die Arbeit Hinweise, dass der Effekt im Subpallium/Striatum verankert ist. Jedoch ist aufgrund vorliegender und bereits publizierter Daten anzunehmen, dass im Falle der einzelnen Kandidaten, zum Teil unterschiedliche Me-chanismen wie die Transmittersynthese, die Transmitterfreisetzung, die Synapsenbildung und die Expression synaptischer Komponenten betroffen sind. Interessanterweise scheinen die durch die Kandidaten betroffenen Signalwege außerdem, laut erhobener Daten, am Wirkmechanismus von Methylphenidat beteiligt zu sein. Kurzum, die vorliegende Dissertation identifiziert die Beeinträchtigung GABAerger Signalübertragung eines, mutmaßlich subpallialen/striatalen aktivitäts-regulierenden neuronalen Netzwerks als neurobiologische Grundlage ADHS-assoziierter Hyperaktivität. Gleichzeitig präsentiert die Arbeit diese Prozesse als funktionelles Bindeglied zwischen der genetischen Veränderung von GRM8, FOXP2 und GAD1 und Hyperaktivität in ADHS. Folglich sind die entwicklungs- und neurobiologischen Mechanismen rund um die GABAerge Übertragung in diesem Netzwerk, und in diesem Zusammenhang die Funktion von Grm8a, (Grm8b), Foxp2 und Gad1b, spannende Ziele für zukünftige Projekte zur Erforschung der Ätiopathogenese und der Entwicklung neuer Therapien von Hyperakti-vität in ADHS. Neben der Rolle in ADHS-assoziierter Hyperaktivität, präsentieren die erhobenen Verhaltensdaten Grm8a, Grm8b und Gad1b außerdem, als interessante Kandidaten für die Erforschung komorbider Angststörung in ADHS. Foxp2 dagegen, wurde mit Hilfe einer Genexpressionsanalyse als Regulator zahlreicher ADHS Risikogene und Entwicklungsstörungs-übergreifenden genetischen und funktionellen Netzwerken, mit möglicher Relevanz für die Polygenie und Komorbidität von ADHS, identifiziert. Im Allgemeinen schafft die vorliegende Dissertation mit der Bestimmung der Genexpressionsmuster und Etablierung und Validierung der (genetischen) Zebrafischmodelle für Grm8a, Grm8b, Foxp2 und Gad1b die Grundlage, diese und weitere Aspekte in zukünftigen Forschungsprojekten zu untersuchen. Beispielsweise die Identifizierung der Netzwerke und Mechanismen, mit dessen Hilfe Grm8a, (Grm8b), Foxp2 und Gad1b in die GABAerge Signalübertragung eingreifen und so letztlich die Aktivität beeinflussen. KW - ADHD KW - Zebrafish KW - FOXP2 KW - GRM8 KW - GAD1 KW - Genetic etiology KW - Animal model KW - Thigmotaxis KW - Locomotor activity KW - Hyperactivity Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-257168 ER - TY - THES A1 - Mai, Marion T1 - Mutationsanalyse der Gene Connexin 36 (CX36) und Tyrosinkinase 3 (TYRO3) als Kandidatengene für periodische Katatonie T1 - mutational analysis of connexin 36 and tyrosinkinase3 as susceptibility genes for periodic catatonie N2 - Das humane Chromosom 15 wurde bereits im Zusammenhang mit anderen Erkrankungen wie dem Marfan Syndrom und der Tay Sachs Erkrankung erwähnt. Für deren Genese wurden auf dem Chromosom gelegene Gene verantwortlich gemacht (Richard et al. 1994). Aufbauend auf den Vorarbeiten der Würzburger Arbeitsgruppe (Stöber et al. 2000, 2002; Meyer et al. 2002) wurden auf Chromosom 15 anhand der Lokalisation, der Funktion und dem Vorhandensein im Zentralnervensystem die Gene Cx36 und TYRO3 für die Mutationsanalyse ausgewählt, um sie nach der Methode von Sanger (Sanger et al. 1977) zu sequenzieren. Sowohl Cx36 als auch TYRO3 spielen eine zentrale Rolle in der Entwicklung und Zellinteraktion im ZNS. Es wäre denkbar, daß ein Defekt während der Synaptogenese im ZNS an der Krankheitsentstehung beteiligt ist, ebenso wie eine unzureichende Ausbildung von Gap junctions, an denen Cx36 maßgeblich beteiligt ist. Die Patienten-DNA wurde aus Blutproben von Probanden mit periodischer Katatonie gewonnen. Diese wurden aus der Familie 11 der bereits erwähnten Studie rekrutiert, die in drei Generationen von der Erkrankung betroffen ist und zehn gesunde, sowie 7 kranke Mitglieder zählt. Die Proben wurden zusammen mit solchen von gesunden Kontrollpersonen vergleichend sequenziert und auf Übereinstimmung mit den Einträgen der GenBank überprüft mit dem Ziel, Mutationen zu finden, die zu einem Defekt im Protein führen und zur Ausprägung der Krankheit beitragen, bzw. die Gene als Kandidaten auszuschließen. N2 - Human chromosome 15 is known as a susceptibility locus for periodic catatonia according to leonhard classification. We sequenced 2 genes, located on chromosome 15 in order to find polymorphisms as underlying cause for periodic catatonia. Both genes, connexin 36 and tyrosinkinase 3 are highly expressed in the human brain. KW - Tyrosinkinase Connexin KW - Gehirn KW - periodische Katatonie KW - Mutationsanalyse KW - Tyrosinkinase KW - Connexin KW - brain KW - schizophrenie Y1 - 2005 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-18046 ER - TY - JOUR A1 - McNeill, Rhiannon V. A1 - Ziegler, Georg C. A1 - Radtke, Franziska A1 - Nieberler, Matthias A1 - Lesch, Klaus‑Peter A1 - Kittel‑Schneider, Sarah T1 - Mental health dished up — the use of iPSC models in neuropsychiatric research JF - Journal of Neural Transmission N2 - Genetic and molecular mechanisms that play a causal role in mental illnesses are challenging to elucidate, particularly as there is a lack of relevant in vitro and in vivo models. However, the advent of induced pluripotent stem cell (iPSC) technology has provided researchers with a novel toolbox. We conducted a systematic review using the PRISMA statement. A PubMed and Web of Science online search was performed (studies published between 2006–2020) using the following search strategy: hiPSC OR iPSC OR iPS OR stem cells AND schizophrenia disorder OR personality disorder OR antisocial personality disorder OR psychopathy OR bipolar disorder OR major depressive disorder OR obsessive compulsive disorder OR anxiety disorder OR substance use disorder OR alcohol use disorder OR nicotine use disorder OR opioid use disorder OR eating disorder OR anorexia nervosa OR attention-deficit/hyperactivity disorder OR gaming disorder. Using the above search criteria, a total of 3515 studies were found. After screening, a final total of 56 studies were deemed eligible for inclusion in our study. Using iPSC technology, psychiatric disease can be studied in the context of a patient’s own unique genetic background. This has allowed great strides to be made into uncovering the etiology of psychiatric disease, as well as providing a unique paradigm for drug testing. However, there is a lack of data for certain psychiatric disorders and several limitations to present iPSC-based studies, leading us to discuss how this field may progress in the next years to increase its utility in the battle to understand psychiatric disease. KW - hiPSC KW - iPSC KW - stem cells KW - mental disorders KW - affective disorders KW - ADHD Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-235666 SN - 0300-9564 VL - 127 ER - TY - JOUR A1 - Melfsen, Siebke A1 - Jans, Thomas A1 - Romanos, Marcel A1 - Walitza, Susanne T1 - Family relationships in selective mutism — a comparison group study of children and adolescents JF - Children N2 - Selective mutism (SM) mostly develops early in childhood and this has led to interest into whether there could be differences in relationships in families with SM compared to a control group without SM. Currently, there are merely few empirical studies examining family relationships in SM. A sample of 28 children and adolescents with SM was compared to 33 controls without SM. The groups were investigated using self-report questionnaires (Selective Mutism Questionnaire, Child-Parent Relationship Test—Child Version) for the assessment of SM and family relationships. Children with SM did not report a significantly different relationship to their mothers compared with the control group without SM. However, the scores in respect to the relationship to their fathers were significantly lower in cohesion, identification and autonomy compared with children without SM. Relationships in families with SM should be considered more in therapy. KW - selective mutism KW - family relations KW - parents KW - schoolchildren Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-290386 SN - 2227-9067 VL - 9 IS - 11 ER - TY - JOUR A1 - Melfsen, Siebke A1 - Kühnemund, Martina A1 - Schwieger, Judith A1 - Warnke, Andreas A1 - Stadler, Christina A1 - Poustka, Fritz A1 - Stangier, Ulrich T1 - Cognitive behavioral therapy of socially phobic children focusing on cognition: a randomised wait-list control study N2 - Background: Although literature provides support for cognitive behavioral therapy (CBT) as an efficacious intervention for social phobia, more research is needed to improve treatments for children. Methods: Forty four Caucasian children (ages 8-14) meeting diagnostic criteria of social phobia according to the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; APA, 1994) were randomly allocated to either a newly developed CBT program focusing on cognition according to the model of Clark and Wells (n = 21) or a wait-list control group (n = 23). The primary outcome measure was clinical improvement. Secondary outcomes included improvements in anxiety coping, dysfunctional cognitions, interaction frequency and comorbid symptoms. Outcome measures included child report and clinican completed measures as well as a diagnostic interview. Results: Significant differences between treatment participants (4 dropouts) and controls (2 dropouts) were observed at post test on the German version of the Social Phobia and Anxiety Inventory for Children. Furthermore, in the treatment group, significantly more children were free of diagnosis than in wait-list group at post-test. Additional child completed and clinician completed measures support the results. Discussion: The study is a first step towards investigating whether CBT focusing on cognition is efficacious in treating children with social phobia. Future research will need to compare this treatment to an active treatment group. There remain the questions of whether the effect of the treatment is specific to the disorder and whether the underlying theoretical model is adequate. Conclusion: Preliminary support is provided for the efficacy of the cognitive behavioral treatment focusing on cognition in socially phobic children. Active comparators should be established with other evidence-based CBT programs for anxiety disorders, which differ significantly in their dosage and type of cognitive interventions from those of the manual under evaluation (e.g. Coping Cat). KW - Verhaltenstherapie Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-68747 ER -